Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cysteine peptidase, putative | 0.0065 | 0.1465 | 1 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.0124 | 0.3275 | 0.3275 |
Plasmodium vivax | vivapain-2 | 0.0017 | 0 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0124 | 0.3275 | 0.3275 |
Entamoeba histolytica | glycogenphosphorylase, putative | 0.0053 | 0.112 | 0.342 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0053 | 0.112 | 0.342 |
Trypanosoma cruzi | cruzipain precursor, putative | 0.0065 | 0.1465 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0269 | 0.774 | 0.774 |
Giardia lamblia | Glycogen phosphorylase | 0.0124 | 0.3275 | 0.5 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0124 | 0.3275 | 0.3275 |
Schistosoma mansoni | glycogen phosphorylase | 0.0053 | 0.112 | 0.1447 |
Echinococcus granulosus | glycogen phosphorylase | 0.0124 | 0.3275 | 0.3275 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0124 | 0.3275 | 1 |
Trypanosoma cruzi | cysteine peptidase, clan CA, family C1, cathepsin L-like, putative | 0.0059 | 0.1293 | 0.8824 |
Plasmodium vivax | vivapain-2 | 0.0017 | 0 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.0269 | 0.774 | 1 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Trypanosoma cruzi | major cysteine proteinase, putative | 0.0051 | 0.104 | 0.7098 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Brugia malayi | carbohydrate phosphorylase | 0.0124 | 0.3275 | 1 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.005 | 0.1019 | 0.1316 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0269 | 0.774 | 0.774 |
Leishmania major | cathepsin L-like protease | 0.0065 | 0.1465 | 1 |
Schistosoma mansoni | glycogen phosphorylase | 0.0124 | 0.3275 | 0.4231 |
Onchocerca volvulus | 0.005 | 0.1019 | 0.311 | |
Leishmania major | cathepsin L-like protease | 0.0065 | 0.1465 | 1 |
Plasmodium falciparum | cysteine proteinase falcipain 3 | 0.0017 | 0 | 0.5 |
Mycobacterium ulcerans | glycogen phosphorylase GlgP | 0.0053 | 0.112 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.1019 | 0.311 |
Toxoplasma gondii | cathepsin CPL | 0.0017 | 0 | 0.5 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0124 | 0.3275 | 1 |
Chlamydia trachomatis | glycogen phosphorylase | 0.0124 | 0.3275 | 0.5 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.0124 | 0.3275 | 0.3275 |
Mycobacterium tuberculosis | Probable glycogen phosphorylase GlgP | 0.0053 | 0.112 | 0.5 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.0124 | 0.3275 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.0269 | 0.774 | 1 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0124 | 0.3275 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.0269 | 0.774 | 1 |
Plasmodium falciparum | cysteine proteinase falcipain 2a | 0.0017 | 0 | 0.5 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.0124 | 0.3275 | 1 |
Echinococcus multilocularis | tumor protein p63 | 0.0343 | 1 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0269 | 0.774 | 0.774 |
Trypanosoma cruzi | cysteine peptidase, putative | 0.0065 | 0.1465 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.0269 | 0.774 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0269 | 0.774 | 0.774 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0269 | 0.774 | 0.774 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0269 | 0.774 | 0.774 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.0124 | 0.3275 | 0.3275 |
Leishmania major | cathepsin L-like protease | 0.0065 | 0.1465 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0124 | 0.3275 | 1 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Trypanosoma cruzi | cysteine peptidase, putative | 0.0065 | 0.1465 | 1 |
Schistosoma mansoni | glycogen phosphorylase | 0.0124 | 0.3275 | 0.4231 |
Trypanosoma brucei | cysteine peptidase, Clan CA, family C1, Cathepsin L-like | 0.0065 | 0.1465 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0053 | 0.112 | 0.342 |
Plasmodium falciparum | cysteine proteinase falcipain 2b | 0.0017 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 6.71 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 7.09 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 7.35 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 11 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 93 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 99 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 3.62 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 0 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 11 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 93 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 99 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.3 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.4962 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.